Input or output interoperability
DICOM is explicitly referenced in the described input, output, or workflow.
exact submission · checked 2026-09-01The model card does not establish every supported DICOM object, transfer method, or local interface.
FDA-cleared profile
icobrain aria
icometrix NV
Authorized purpose: Provides concurrent CADe/CADx aid for trained radiologists detecting, assessing, and characterizing ARIA-E and ARIA-H on brain MR images.
Evidence status: each field states its source quality, applicability, and review date. Research pending, information not established, and vendor documentation pending remain distinct outcomes.
Product overview
Start with the essentials
Authorized purpose: Provides concurrent CADe/CADx aid for trained radiologists detecting, assessing, and characterizing ARIA-E and ARIA-H on brain MR images.
Overview status: Source-reviewed overview
- What does this software do? Authorized purpose: Provides concurrent CADe/CADx aid for trained radiologists detecting, assessing, and characterizing ARIA-E and ARIA-H on brain MR images.
- Which images or clinical context are in scope? Modality: MRI Anatomy or clinical context: Brain Input: Two-time-point DICOM brain MRI using FLAIR for ARIA-E and T2*-GRE for ARIA-H.
- Who uses it? Intended users: Trained radiologists.
- What does the software produce? Output: Annotated DICOM overlays and an electronic report containing measurements and severity findings.
- What is its most important limitation? Key limitation: Adjunctive only, not an independent interpretation; not intended for macrohemorrhages at least 10 mm, and nonconforming sequences generate warnings.
Clinical takeaway
Clinical role: Provides concurrent CADe/CADx aid for trained radiologists detecting, assessing, and characterizing ARIA-E and ARIA-H on brain MR images.
Evidence takeaway
Evidence from the reviewed source record: An MRMC study included 199 cases and 16 readers; assisted versus unassisted sensitivity was 86.5%/70.9% for ARIA-E and 79.0%/68.7% for pooled ARIA-H.
Clinical details
What this tool is for
Start with the authorized purpose, then verify how it fits your service line and reading workflow.
- Exact purpose
- Provides concurrent CADe/CADx aid for trained radiologists detecting, assessing, and characterizing ARIA-E and ARIA-H on brain MR images.
Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.
- Intended users
- Trained radiologists.
FDA packet user statement.
- Care setting and population
- Adult
Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.
- Workflow role
- Detection, localization, or diagnostic support
Conservative normalization of explicit wording in an exact-submission source.
- Required input
- Two-time-point DICOM brain MRI using FLAIR for ARIA-E and T2*-GRE for ARIA-H.
Exact FDA input and sequence scope.
- Output and human action
- Annotated DICOM overlays and an electronic report containing measurements and severity findings.
FDA output description.
- Limitations
- Adjunctive only, not an independent interpretation; not intended for macrohemorrhages at least 10 mm, and nonconforming sequences generate warnings.
Exact FDA limitation boundary.
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Implementation
Questions for IT, informatics, and operations
Use these fields to structure a vendor demo, security review, and implementation estimate.
- Integration
- The exact-submission ACR model card explicitly references DICOM and PACS in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
- Deployment and data flow
- On-premise
Deployment category preserved from the prior exact-submission review; hosting region, data flow, and current commercial configuration still require vendor confirmation.
- Security and privacy
- Vendor documentation pending
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
- Training and support
- Vendor documentation pending
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
- Monitoring and change control
- Vendor documentation pending
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Result destination
PACS is explicitly referenced as a result destination.
exact submission · checked 2026-09-01Confirm supported products, versions, routing behavior, and display requirements during local evaluation.
ACR exact-submission catalog context
ACR AI Central provides an exact-submission model card for icobrain aria; FDA labeling remains controlling for clinical use, limitations, and performance.
exact submission · checked 2026-09-09Evidence
Performance evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
- Evidence summary
- An MRMC study included 199 cases and 16 readers; assisted versus unassisted sensitivity was 86.5%/70.9% for ARIA-E and 79.0%/68.7% for pooled ARIA-H.
FDA packet performance summary.
- Reported sensitivity
- 70.9%; 70.2%
Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.
- Reported specificity
- 80%; 76.7%; 79.0%
Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
icobrain aria regulatory performance study summary
- DesignReader Study
- PopulationAdult
- Scopeexact submission
- Tested version1
- IndependenceIndependence not established
K240712
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Costs and setup
Budget and ongoing governance
These are common procurement questions; unknown values remain visible until a source supports them.
- Pricing and total cost
- Vendor documentation pending
No public price or quote for the exact K240712 configuration was established in this review.
- Reimbursement and coding
- Not established in reviewed sources
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
- Postmarket safety review
- The exact-identifier FDA recall query returned no native recall record for K240712. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
Buyer worksheet
Open questions to take to the vendor
- Verify security and privacy controls: Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
- Verify training: Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
- Verify pricing and total cost: No public price or quote for the exact K240712 configuration was established in this review.
- Verify reimbursement and coding relevance: No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
- Verify local validation and lifecycle monitoring: Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Research record
What has been checked
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Sources & history
How this profile was documented
Open the ledger for source dates, scope, and research-record updates.
View source ledger and history
Source ledger
-
FDA K240712: icobrain aria
Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary
-
Artificial Intelligence-Enabled Medical Devices
Scope: regulatoryIdentity, modalityContext
-
icobrain aria model card (K240712)
Scope: intendedUsers, careSetting, output, limitations, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities
-
PubMed biomedical literature index
Scope: evidenceDiscovery
-
ClinicalTrials.gov study registry
Scope: evidenceDiscovery, studyStatus
-
openFDA Device Recall API
Scope: recallDiscovery, nativeSubmissionMatching
-
openFDA exact recall query for K240712
Scope: postmarketSafety
Research history
-
K240712 FDA decision
Regulatory record
510(k)
-
Source-review record updated
Research record
fda record reviewed
-
Reader overview source-reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Related tools to compare
FDA-cleared K261405
ANDI 2.2
Imeka Solutions, Inc.
ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained...
- Modality
- MRI
- Anatomy
- Brain
- Decision
- 2026-05-28
FDA-cleared K260032
Morph
BeauBrain Healthcare, Inc.
Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it...
- Modality
- MRI
- Anatomy
- Brain
- Decision
- 2026-05-13
FDA-cleared K253057
AI-Rad Companion Brain MR
Siemens Healthcare GmbH
Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.
- Modality
- MRI
- Anatomy
- Brain
- Decision
- 2026-01-22
FDA-cleared K253489
Swoop® Portable MR Imaging® System
Hyperfine, Inc.
Swoop Portable MR Imaging System provides ultra-low-field point-of-care head MRI for all ages and includes deep-learning T1, T2, FLAIR, and DWI reconstruction.
- Modality
- MRI
- Anatomy
- Brain
- Decision
- 2025-12-12